戻る Agenda
Session 8: ABSTRACT SESSION
Session Chair(s)
Lisa Melanie Harinstein, PharmD
Team Leader, Division of Pharmacovigilance, FDA
FDA, United States
For the first time at the DIA Pharmacovigilance and Risk Management Strategies Conference, this new session will feature four presentations selected from an abstract submission process. This session will explore the innovative use of pharmacoepidemiology studies, real world evidence, social media, and signal management tools in pharmacovigilance.
Speaker(s)
Ruben Ayzin Rosoky, MD, PhD
Novartis, France
Global Program Safety Lead
The European IV Iron PASS Consortium: Experiences from Coordinating a Multi-Company, Multi-Registry PASS
Michael Forstner, PhD, MPH, MSc
Mesa Laubela-Consulting, Switzerland
Managing Director, Head of Pharmacoepidemiology Practice
Innovative Pharmacovigilance (PV) Solution in Social Media: Compliance, Signaling, and Social Media Footprint
Jennifer B Hannan, MS
Merck & Co., Inc., United States
Director, Pharmacovigilance Business Liaison
Evaluation of Different Signal Management Tools: New Regulatory Perspectives
Sanjeev Miglani, MD
AWINSA Life Sciences, United States
Founder and Director
The Value of RWD in Safety Signal Refinement
Irene Cosmatos, MS
UBC, United States
Senior Director, Epidemiology & Real-World Evidence